益气健脾法治疗FD的临床疗效及对血浆MOT、GAS及SS的影响

Observation of the Clinical Efficacy on Functional Dyspesia Treated with the Therapy for Benefiting Qi and Strengthening the Spleen

目的观察益气健脾法治疗功能性消化不良(FD)的临床疗效及其对血浆胃动素(MOT)、胃泌素(GAS)及生长抑素(SS)的影响。方法将160例FD患者随机分为两组,每组80例。予对照组患者枸橼酸莫沙必利分散片及氟哌噻吨美利曲辛片口服。治疗组在上述基础上给予自拟益气健脾中药治疗。两组均连用4周为1个疗程,1个疗程后比较疗效及检测血浆血浆MOT、GAS及SS。结果治疗结束后,两组患者总有效率比较差异有统计学意义(P<0.05);两组患者治疗后主要症状积分较本组治疗前均明显下降(P<0.05),且治疗组优于对照组;两组患者治疗后MOT较本组治疗前明显升高,SS明显降低,且治疗组优于对照组(P<0.05)。结论枸橼酸莫沙必利分散片、氟哌噻吨美利曲辛片联合益气健脾中药治疗功能性消化不良临床疗效确切,安全可靠,不良反应少,值得进一步推广。

Objective To observe the clinical efficacy on functional dyspesia（FD） treated with the therapy for benefiting qi and strengthening the spleen and the impacts on plasma motilin （MOT） , gastrin （GAS） and somatostatin （SS）. Methods One hundred and sixty cases of FD were randomized into two groups,80 cases in each group. In the control group, Mosapride Citrate Tablets and Flupentixol and Melitra-cen Tablets were prescribed. In the treatment group, on the basic treatment as the control group, the self - prepared herbal medicine for benefiting qi and strengthening the spleen was supplemented. The treatment of 4 weeks made 1 session in the two groups. After 1 session treatment, the efficacy was compared and plasma MOT, GAS and SS levels were detected. Results At the end of treatment, the difference in the total effective rate was significant between the two groups（ P 〈 0.05 ）. The main symptom score after treatment was reduced apparently as compared with that before treatment in the two groups （ P 〈 0.05 ）, and the result in the treat-ment group was superior to the control group. MOT level after treatment was increased apparently as compared with that before treatment in the same group, and SS level was reduced obviously. The results in the treatment were better than those in the control group（ P 〈 0.05 ）. Conclusion Mosapride Citrate Tablets, Flupentixol and Melitracen Tablets combined with the self - prepared herbal medicine for benefiting qi and strengthening the spleen achieve the definite clinical efficacy, reliable safety and less adverse reactions in the treatment of FD. Hence, the combined medication deserves a further promotion.